Biotech Divergence?

When it comes to the S&P 500 and one of the ETFs that represents the overall biotech sector (the iShares Nasdaq Biotechnology ETF), the author of today’s article observes that “the paths of these two investments appear to be diverging.” Given this apparent divergence, he questions whether, despite all the recent medical news, biotech stocks have already had their run. For more, CLICK HERE.

“Embrace The Uncertainty” With These 2 Stocks With Over 100% Upside Potential

When it comes to the uncertainty that currently permeates the market as a result of the pandemic and impending election, the chief investment strategist at Oppenheimer is choosing to embrace it. As a result, today’s article takes a look at two specific stocks Oppenheimer is bullish on – and which its analysts believe have over 100% upside potential (792% in the case of one of the stocks!). For these two stocks – a clinical-stage biopharmaceutical company and a clinical-stage gene therapy company – CLICK HERE.

Could These 2 Ultra-Risky Biotech Stocks Make Investors Ultra Wealthy?

Both of the stocks highlighted in today’s article are clinical-stage biotechs, both are developing products to address the coronavirus pandemic (a vaccine in one case and a therapeutic in the other) – and both are “ultra-risky”. So what are the chances that either – or both – of these two ultra-risky stocks could make investors ultra wealthy? For more on these two stocks – one of which just made its market debut – CLICK HERE.

5 Low-Priced, Big-Upside Biotech And Medtech Stocks “For Very Aggressive Accounts”

“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count,” notes the author of today’s article. He proceeds to highlight five low-priced biotech and medtech stocks with significant upside potential to consider for very aggressive accounts. For these five stocks – including a clinical-stage biopharmaceutical company working on a potential blockbuster treatment for post-traumatic stress disorder – CLICK HERE.

The Dominator & The Disruptor: 2 Biotech Stocks To Consider For Market-Beating Returns

One of the biotech stocks highlighted in today’s article is a well-established, large-cap name. The other is a far less established, small-cap player with no products currently on the market. What the two have in common, according to the author, is that both “have made significant breakthroughs — and could provide market-beating returns for many years to come as a result.” For these two biotech stocks to consider – one that currently dominates the cystic fibrosis market and one that is likely to disrupt the diabetes market – CLICK HERE.

Bad News For Its Competitor Could Be Great News For This Small-Cap Biotech – And Its Shareholders

In January, the small-cap biotech highlighted in today’s article received FDA approval for its treatment for childhood peanut allergy – and with peanut allergy being the most common food allergy in the U.S. (with cases of the condition rising rapidly) and the fact that this is currently the only FDA-approved treatment for the condition (thanks to a competitor encountering some regulatory roadblocks), this drug has the potential to become a blockbuster product. For more, CLICK HERE.

ETFs: A Remedy For Biotech Risks

The solution to the substantial risks associated with biotech stocks (especially small biotech firms)? Biotech ETFs! Today’s article highlights six biotech ETFs to consider buying, noting that “Some provide well-rounded access to the space, while others acutely focus on certain aspects of the space, such as cancer treatments or drugs to battle infectious diseases.” For these six biotech ETFs, CLICK HERE.

A Look At One Of The Newest COVID-19 Stocks

Joining the ever-expanding list of COVID-19 stocks is this biotech that has filed an application with the FDA for initiation of Phase 2/Phase 3 clinical trials for its experimental monoclonal antibody therapy for the disease. The safety and tolerability of the therapy has already been demonstrated and, as today’s article explains, the company believes that its modulating effect “could reduce the number of ICU patients and decrease the need for mechanical ventilation, ultimately saving lives.” For more, CLICK HERE.

This Little-Known Biotech’s Blood Plasma-Based Coronavirus Therapy Could Soon Bring It A Lot Of Attention

2020-08-03 10_28_24-Laboratory Test Tubes · Free Stock PhotoOf all the companies working on the development of potential COVID-19 vaccines and therapeutics, the one highlighted in today’s article – a small Israel-based biotech that specializes in blood plasma-based treatments – is one of the least well-known. However, given that plasma-based therapies have already been shown to be effective in treating severe cases of COVID-19, this company could start getting a lot more attention as its coronavirus therapy moves on to further clinical testing – and that could send its stock soaring. So is this stock a smart buy? CLICK HERE.